false
0002010788
0002010788
2026-11-13
2026-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
November
13, 2026
EXOZYMES
INC.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
001-42204 |
|
83-4550057 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
750
Royal Oaks Drive, Suite 106
Monrovia,
CA 91016
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (626) 415-1488
Check
the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock |
|
EXOZ |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.07 — Submission of Matters to a Vote of Security Holders
The
2026 Annual Meeting of Stockholders (the “Annual Meeting”) of eXoZymes Inc. (the “Company”) was held on November
13, 2026. At the Annual Meeting, the Company’s shareholders:
| |
● |
Elected
six nominees to serve as directors until the 2027 annual meeting of shareholders and until their successors are duly elected and qualified;
and |
| |
|
|
| |
● |
Ratified
the appointment of RBSM LLP, as our independent registered public accounting firm, for our fiscal year ending December 31, 2026.
|
There
were outstanding, as of the close of business on September 15, 2026, the record date for the Annual Meeting, 9,304,701 shares of Common
Stock of the Company, each entitled to one vote per shares. There were present at the Annual Meeting, either in person or represented
by proxy, 6,393,039 votes, representing 68.70% of the shares entitled to vote at the Annual Meeting.
Proposals
1 had 340,251 broker non-votes.
The
final number of votes cast for, against, withheld or abstaining with respect to each Proposal is set forth below.
| Proposal 1 | |
Shares For | | |
Shares Against | | |
Shares Abstaining | | |
Broker non-voting | |
| Christopher A. Marlett | |
| 6,050,804 | | |
| 654 | | |
| 1,330 | | |
| 340,251 | |
| Anthony DiGiandomenico | |
| 6,045,885 | | |
| 6,627 | | |
| 276 | | |
| 340,251 | |
| James U. Bowie | |
| 6,048,086 | | |
| 4,015 | | |
| 687 | | |
| 340,251 | |
| James J. Lalonde | |
| 6,050,082 | | |
| 2,019 | | |
| 687 | | |
| 340,251 | |
| Lon E. Bell | |
| 6,049,992 | | |
| 2,109 | | |
| 687 | | |
| 340,251 | |
| Edgardo Rayo | |
| 6,047,658 | | |
| 4,553 | | |
| 577 | | |
| 340,251 | |
| Proposal 2 | |
Shares For | | |
Shares Against | | |
Shares Abstaining | |
| Ratification of the appointment of RBSM LLP, as our independent registered public accounting firm, for our fiscal year ending December 31, 2026. | |
| 6,391,977 | | |
| 500 | | |
| 562 | |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
November 19, 2026 |
EXOZYMES
INC. |
| |
|
|
| |
By |
/s/
Fouad Nawaz |
| |
|
Fouad
Nawaz |
| |
|
VP
of Finance (Principal Financial and Accounting Officer) |